The firm presented data at AACR this week showing the improved performance of its molecular pancreatic cancer early detection assay.

The tests use AI-powered algorithms to analyze digital histopathology images, along with patient clinical data.

With the next PAMA data collection period starting in May, reporting by hospital labs in particular will be essential, but their level of participation remains uncertain.

NEW YORK — Solvd Health said on Tuesday that it has received approval from the US Food and Drug Administration to offer its AvertD pharmacogenomic test for opioid use disorder (OUD) using blood ...

At AACR, Guardant Health and a Japanese group showcased data on machine learning models that predict the tissue of origin in cancers of unknown primary.

Last week, readers were most interested in a story about Roche expanding the cancer testing portfolio of subsidiary Foundation Medicine by buying Saga Diagnostics.

The Utrecht, Netherlands-based company recently closed a $70 million funding round and published trial results showing its technology's equivalence to manual blood collection.

The companies have developed the SmartChip Biosecurity Platform, which combines Takara's instrumentation with Resistomap's software.

Roche's Foundation Medicine will strengthen its testing portfolio by adding Saga's Pathlight tumor-informed molecular residual disease platform.

Pathologists at academic medical centers are using intentional change-management strategies to overcome some intangible barriers digital uptake.

Siemens said the has been " substantial progress in the preparation of the unprecedented transaction structure … [and] The separation process is advanced." ...

The expanded panel includes 93 new microorganism-drug combinations, bringing the total panel size to 215, and in conformity with all the most current FDA breakpoints.